Takeda Pharmaceutical Company Limited

Thank you very much for joining us today for Takeda's 2026 Q2 earnings announcement, despite your busy schedules. My name is O'Reilly, head of IR. I'll be serving as the MC today. Thank you for this opportunity. I would like to explain about the language setting first. Please find the language selection button at the bottom of your Zoom window. If you wish to listen to Japanese, please select Japanese. If English, please select English. And if you want to listen to the original voice, please turn it off. Before starting, I would like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those discussed today.

The factors that could cause our actual results to differ materially are discussed in our most recent Form 20F and in our other SEC findings. Please also refer to the important notice on page 2 of the presentation regarding forward-looking statements and our non-IFRS finance measures, which will also be discussed during this call. Definitions of our non-IFRS measures and reconciliations with the comparable IFRS financial measures are included in the appendix to that presentation. Now we would like to start today's presentation. We will hear from President and CEO Julie Kim, Chief Financial Officer Miran Furuta, and R&D President Andy Plump. And this will be followed by a Q&A session. Now we'll get started.